Fetal hemoglobin (Hb F) levels increase in most patients with sickle cell disease following intermittent butyrate therapy. Although the full effects of butyrate on Hb F levels usually require multiple treatment cycles, in some patients a peak level is achieved after a few days of butyrate therapy. Our investigation of the mechanism(s) responsible for this rapid induction of Hb F by butyrate showed that reticulocyte gamma-globin chain synthesis markedly increased within 24 hours of butyrate exposure, without concomitant changes in reticulocyte gamma-globin mRNA levels. This suggests that butyrate might induce Hb F by increasing the efficiency of translation of gamma-globin mRNA. This hypothesis was confirmed by ribosome loading studies that demonstrated enrichment of the polysomal fraction of reticulocytes with gamma-globin mRNA following butyrate exposure. Thus, the induction of Hb F by butyrate may be mediated by translational effects in addition to its well-known effects on transcription of the gamma-globin genes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2826269 | PMC |
| http://dx.doi.org/10.1182/blood-2004-02-0454 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Upregulation of miR‑6747‑3p affects red blood cell lineage development and induces fetal hemoglobin expression by targeting BCL11A in β‑thalassemia.
Mol Med Rep
January 2025
College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian 350004, P.R. China.
Article Synopsis
- - In β-thalassemia, excessive α-globin chains disrupt the development of red blood cells, leading to anemia, and altered levels of miRNAs like miR-6747-3p have been observed in patients with this condition.
- - The study confirmed higher expression levels of miR-6747-3p in β-thalassemia major patients compared to healthy individuals, revealing its positive correlation with fetal hemoglobin (HbF) levels.
- - Overexpressing miR-6747-3p led to reduced cell proliferation and increased apoptosis, while promoting erythroid differentiation and γ-globin expression by targeting the BCL11A gene, suggesting it could be a potential therapeutic target for β-thal
A Review of Gene Therapies for Hemoglobinopathies.
Hemoglobin
May 2024
Dana-Farber Cancer Institute - Department of Medical Oncology, Boston, MA, USA.
Due to the significant morbidity and mortality of hemoglobinopathies, curative options have long been pursued. The overall goal of gene therapy is to modify a patient's own hematopoietic stem cells to overcome the deleterious effects of the underlying genetic defect by gene addition, gene editing, or gene silencing. Gene addition incorporates genes with superior function than the abnormal gene; gene editing takes advantage of molecular tools such as zinc finger proteins, Transcription Activator-Like Effector Nucleases and Clustered Regularly Interspaced Short Palindromic Repeats coupled with Cas9 proteins (CRISPR-Cas9) which allow for sequence-specific breaks in DNA that disrupt gene function; and gene silencing suppresses gene expression by interference with mRNA transcription/protein translation or epigenetic modification.
View Article and Find Full Text PDFStructure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatment.
Bioorg Med Chem Lett
September 2024
Drug Discovery Chemistry Platform Unit, RIKEN Center for Sustainable Resource Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan. Electronic address:
Article Synopsis
- Researchers focused on developing new inhibitors for lysine methyltransferase G9a, which plays a significant role in epigenetics.
- They improved an existing compound (7a) to create a much more effective inhibitor (7i), which has a low IC value of 0.024 μM, indicating strong potency.
- Studies using X-ray crystallography and SPR showed that 7i binds to G9a differently than other compounds, and it effectively reduced certain histone modifications and increased γ-globin mRNA levels in specific human cells.
Long Non-Coding RNA H19 Leads to Upregulation of γ-Globin Gene Expression during Erythroid Differentiation.
Hemoglobin
January 2024
Medical College, Guizhou University, Guiyang, China.
Long noncoding RNAs (lncRNAs) are important because they are involved in a variety of life activities and have many downstream targets. Moreover, there is also increasing evidence that some lncRNAs play important roles in the expression and regulation of γ-globin genes. In our previous study, we analyzed genetic material from nucleated red blood cells (NRBCs) extracted from premature and full-term umbilical cord blood samples.
View Article and Find Full Text PDFGinsenoside Rg1 promotes fetal hemoglobin production in vitro: A potential therapeutic avenue for β-thalassemia.
Eur J Pharmacol
April 2024
Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, Yunnan Province, China; Medical School, Kunming University of Science and Technology, Kunming, 650500, Yunnan Province, China; Department of Medical Genetics, NHC Key Laboratory of Preconception Health Birth in Western China, Yunnan Provincial Key Laboratory for Birth Defects and Genetic Diseases, First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650032, China. Electronic address:
β-thalassemia, a globally prevalent genetic disorder, urgently requires innovative treatment options. Fetal hemoglobin (HbF) induction stands as a key therapeutic approach. This investigation focused on Ginsenoside Rg1 from the Panax genus for HbF induction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!